Celiac Index

The only current treatment for celiac disease is a lifelong gluten-free diet (GFD). There are no approved medications that cure or replace dietary treatment.

Gluten-Free Diet (GFD)

What to Eliminate

All food/drink containing:

Wheat (all varieties: spelt, durum, khorasan, triticale)
Barley
Rye
Gluten derivatives / additives

What Is Safe

Maize (corn), millet, sorghum, teff, rice, wild rice
Amaranth, quinoa, buckwheat
Potatoes, bananas and other non-cereal carbohydrates
Oats (controversial — see causes)

Thresholds

Individual tolerance varies: some tolerate ~35 mg/day, others cannot tolerate >10 mg/day
Regulatory standard for "gluten-free" labelling: <20 ppm (~6 mg/day at typical servings)
A 90-day threshold trial suggests 50 mg/day is enough to cause measurable mucosal worsening, while 10 mg/day remains a gray zone rather than a guaranteed safe intake
A newer dose-response study suggests that acute immune activation may occur at even lower doses, but symptoms remain unreliable and the long-term meaning of those low-level signals is still being worked out
The practical lesson is to think in terms of repeated total exposure, not ppm alone; see gluten-thresholds

Timeline of Improvement

Symptoms may improve within days to weeks of starting GFD
Antibodies (TTG IgA) decrease within months
Histological healing is slower: villous recovery often takes 1–2 years, and may be substantially slower in older adults

Challenges

Requires significant education, label-reading vigilance, and lifestyle adjustment
Cross-contamination is a major ongoing concern (eating out, shared kitchen surfaces, utensils, fryers, food-service workflow)
GFD can be nutritionally incomplete: common gluten-free substitutes (rice/potato/corn starch) are often lower in fibre and micronutrients, less fortified than conventional products, and sometimes higher in sugars/fats
Dietitian referral is recommended at diagnosis and ongoing
Cost: GF foods significantly more expensive than conventional equivalents
Overly restrictive or hypervigilant eating can itself become a burden, so practical risk calibration matters

Nutritional Supplementation

Many patients need supplementation at diagnosis due to accumulated deficiencies:

Iron
Folate
Zinc, selenium
Vitamin D + calcium
Vitamin B12
Vitamin K, B6, and sometimes vitamin E depending on dietary quality and severity of prior malabsorption

Monitoring

Frequency

Multiple visits/year initially after diagnosis, especially in the first year while the diet and deficiencies are being stabilized
Then roughly every 12–24 months once stable, with earlier reassessment if symptoms persist or recur

What to Monitor

Symptom control and GFD adherence
TTG IgA and related serology — rising levels suggest gluten exposure (though negative TTG ≠ perfect adherence)
Complete blood count, iron panel, liver enzymes, thyroid, vitamin D, and other micronutrients as indicated
DEXA scan — bone mineral density (osteoporosis risk), with particular attention at diagnosis when bone loss risk seems plausible rather than waiting years for complications to declare themselves
Comorbid autoimmune disease surveillance
Quality of life, social/psychological burden, and whether ongoing specialist dietitian input is needed

Vaccinations

Pneumococcal vaccination recommended (increased pneumonia risk in celiac disease)
Routine vaccination schedule maintained

Non-Responsive Celiac Disease (NRCD)

~20–40% of patients experience persistent symptoms despite GFD for ≥6–12 months.

Most common cause: Unintentional gluten ingestion or slow response to healing

Other causes to exclude:

SIBO (small intestinal bacterial overgrowth)
Giardiasis
Disaccharide / FODMAP intolerance
Fructose intolerance
Crohn's disease
Pancreatic insufficiency
Microscopic colitis
Lactose intolerance
Inflammatory bowel disease

Refractory Celiac Disease (RCD)

~1.5% of celiac patients. Persistent malabsorption + villous atrophy despite ≥12 months strict GFD after exclusion of other causes.

	Type 1 RCD	Type 2 RCD
IEL phenotype	Normal / mature phenotype	Abnormal (aberrant or neoplastic IEL population)
Prognosis	Better	Poor — high mortality
EATL risk	Low but not zero	High
Treatment	Open-capsule budesonide first-line; selected immunomodulators such as thiopurine strategies in selected patients	Open-capsule budesonide first-line; cladribine-based or transplant strategies in selected patients

Beyond-GFD Reality Check

A newer broad management review reinforces why adjunctive therapies keep attracting interest: even with self-reported strict diet adherence, a substantial minority of patients still report symptoms, psychosocial burden, or ongoing mucosal injury. That does not mean the gluten-free diet has failed as the core treatment. It means the practical and biologic gap between ideal adherence and real-world control remains large.

Outlook / Cancer Risk

Increased risk of GI cancers: oropharynx, oesophagus, small intestine
Enteropathy-associated T-cell lymphoma (EATL) — most common cancer complication; poor prognosis
Strict GFD adherence reduces (but does not eliminate) cancer risk
Overall mortality increase is inconsistent across studies

Source Basis

Current synthesis incorporates:

raw/1-s2.0-S0016508524003603-main.pdf (Advances in Nonresponsive and Refractory Celiac Disease, 2024), especially for recovery timelines, persistent villous atrophy, and modern NRCD/RCD framing
raw/nutrients-15-02048.pdf (Follow-Up of Celiac Disease in Adults: “When, What, Who, and Where”, 2023), especially for practical follow-up goals, multidisciplinary care, and 12–24 month review intervals
raw/PIIS095362052500038X.pdf (What is new in the management of celiac disease?, 2025), especially for the limits of serology, persistent symptoms, and multidisciplinary management
raw/1-s2.0-S2405457725031602-main.pdf (Understanding cross-contamination in a gluten-free diet: A scoping review, 2026), especially for practical contamination risk framing
raw/jcm-14-04848-v3.pdf (Micronutrient Deficiencies Associated with a Gluten-Free Diet..., 2025), especially for persistent nutritional risk despite treatment
raw/nutrients-17-03530.pdf (High-Quality Nutritional and Medical Care in Celiac Disease Follow-Up, 2025), especially for nutritional quality, psychosocial burden, and preventive care
raw/223_2021_Article_938.pdf (Newly Diagnosed Celiac Disease and Bone Health in Young Adults: A Systematic Literature Review, 2022), especially for the point that low bone density may already be present early and may justify attention at diagnosis rather than only later
raw/biomedicines-14-00029-v2.pdf (Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet, 2026), especially for why beyond-GFD adjuncts continue to matter even when the diet remains the core standard of care
raw/ijms-24-12800.pdf (Old and New Adjunctive Therapies in Celiac Disease and Refractory Celiac Disease: A Review, 2023), especially for grounding the RCD section in the still-imperfect real treatment hierarchy

Backlinks